Health Care

Bruls’ recent 2,644‑share sale at $89.98 reflects a careful, profit‑taking strategy amid Edwards Lifesciences’ rally—what it signals for insiders and investors.

Discover how insider trades by Hanish Arnold C. reveal Omeros’ valuation outlook and range‑bound strategy—insightful for investors eyeing biopharma growth.

Insider Kittu’s zero‑consideration moves keep his stake stable—no price impact, no shift in confidence. Learn how this routine transfer affects BillionToOne shares.

Discover why President Daniel McCarthy’s recent sale of 65,892 Evolent Health shares may signal a quiet liquidity shift, not distress.

Gilde Healthcare’s steady selling of Shoulder Innovations shares signals gradual dilution amid a 4% weekly slide – investors weigh long‑term resilience against shifting insider ownership.

SoftBank’s SVF Pauling sells 6 M Relay shares at $19.40—no impact on price, just routine portfolio rebalancing.

Bailey Calli Sullivan’s modest insider sale after Nakamoto’s reverse split signals confidence in the merger‑driven growth strategy and potential upside for long‑term investors.

Inside Nakamoto Inc.’s latest insider sales: CFO Teresa Gendron’s strategic sell‑off reflects confidence, liquidity management and a bullish outlook for the company’s healthcare focus.

CEO Dudum Andrew’s July 2026 sale of 463k HIMS & HERS HEALTH shares shows strategic divestment, not loss of confidence, and signals a shift in portfolio while the company’s telehealth prospects stay strong.

Insider sales at Tempus AI reveal cautious CEO trading—under 0.5% of holdings yet hint at liquidity planning and future valuation impacts.